Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 451 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
ALX Oncology Holdings Inc.
Market Cap
$162.82M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$153.84M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-76.15%
Market Cap
$172.99M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$173.04M
Gross Margin
63.55%
TTM Avg
56.95%
3Y Avg
54.72%
5Y Avg
65.55%
Market Cap
$152.45M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$152.16M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-29.98%
Market Cap
$174.17M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $162.82M | 0.00% | 0.00% | 0.00% | 0.00% |
| Inogen, Inc. (INGN)vs › | $160.82M | 48.89% | 46.84% | 43.63% | 44.77% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | 0.00% | 0.00% | 0.00% | -76.15% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | 0.00% | 50.00% | 25.00% | 16.67% |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | 63.55% | 56.95% | 54.72% | 65.55% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | 0.00% | 0.00% | 0.00% | -29.98% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | 100.00% | 100.00% | 100.00% | 100.00% |
| Codexis, Inc. (CDXS)vs › | $149.51M | 83.71% | 79.64% | 78.40% | 78.75% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | 99.69% | 100.00% | -73.48% | -190.92% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 9.11% |
| 2020-03-31 | 9.01% |
| 2019-12-31 | 9.07% |
| 2019-09-30 | 9.08% |
| 2019-06-30 | 9.11% |
| 2019-03-31 | 9.11% |
